Drug Trial Radar · NCT01817530
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
Last checked: Nov 19, 2026Latest source record: Jul 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
571
Actual
Start
Apr 8, 2013
Primary completion
Jun 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 51 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of elagolix alone and in combination with add-back therapy versus placebo on heavy menstrual bleeding in premenopausal women 18 to 51 years of age with uterine fibroids.
Conditions
- Heavy Uterine Bleeding
- Uterine Fibroids
Interventions
Elagolix placeboOther
oral coated tablet
ElagolixDrug
oral coated tablet
0.5 mg estradiol / 0.1 mg norethindrone acetateDrug
oral hard capsule
1 mg estradiol / 0.5 mg norethindrone acetateDrug
oral hard capsule
E2/NETA placeboDrug
oral hard capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of < 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final MonthTime frame: Baseline, Final Month (last 28 days of treatment)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.